Company · morphotek-cf9bdcc4
Morphotek
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. Morphotek. Companies, record morphotek-cf9bdcc4. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/morphotek-cf9bdcc4
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Morphotek
- Trials
- 21
- As lead sponsor
- 21
- As collaborator
- 0
- Recruiting
- 0
- Active, recruiting or not
- 0
- Completed
- 13
- Stopped early, withdrawn or suspended
- 8
- Posted results
- 11
- Trials by phase
- Phase 1 10, Phase 2 10, Phase 3 1
- Drugs its trials test
- 12
- Comparisons calculated in its trials
- 9
- First trial registered
- 2006-04-26
- Last update
- 2024-03-29
Source ClinicalTrials.gov
Pipeline12
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| FARLETUZUMAB | Phase 3 | 8 | 8 | 0 | FOLR1 | Folate receptor alpha inhibitor | https://conductscience.org/library/drugs/CHEMBL1743016 | Open Targets |
| CARBOPLATIN | Phase 3 | 3 | 3 | 0 | https://conductscience.org/library/drugs/CHEMBL1351 | Open Targets | ||
| AMATUXIMAB | Phase 2 | 5 | 5 | 0 | MSLN | Mesothelin inhibitor | https://conductscience.org/library/drugs/CHEMBL1742984 | Open Targets |
| ONTUXIZUMAB | Phase 2 | 4 | 4 | 0 | CD248 | Endosialin inhibitor | https://conductscience.org/library/drugs/CHEMBL2364659 | Open Targets |
| CISPLATIN | Phase 2 | 2 | 2 | 0 | https://conductscience.org/library/drugs/CHEMBL11359 | Open Targets | ||
| DOCETAXEL | Phase 2 | 2 | 2 | 0 | TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | Tubulin inhibitor | https://conductscience.org/library/drugs/CHEMBL3545252 | Open Targets |
| GEMCITABINE | Phase 2 | 2 | 2 | 0 | POLA1, POLA2, POLD1, POLD2, POLD3, POLD4, POLE, POLE2, POLE3, PRIM1, PRIM2, RRM1, RRM2, RRM2B | DNA polymerase (alpha/delta/epsilon) inhibitor; Ribonucleoside-diphosphate reductase RR1 inhibitor | https://conductscience.org/library/drugs/CHEMBL888 | Open Targets |
| PACLITAXEL | Phase 2 | 2 | 2 | 0 | TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 | Tubulin inhibitor | https://conductscience.org/library/drugs/CHEMBL428647 | Open Targets |
| PEMETREXED | Phase 2 | 2 | 2 | 0 | DHFR, GART, TYMS | Dihydrofolate reductase inhibitor; GAR transformylase inhibitor; Thymidylate synthase inhibitor | https://conductscience.org/library/drugs/CHEMBL225072 | Open Targets |
| DOXORUBICIN | Phase 1 | 1 | 1 | 0 | TOP2A | DNA topoisomerase II alpha inhibitor | https://conductscience.org/library/drugs/CHEMBL53463 | Open Targets |
1 to 10 of 12
See all 12 pipelineTrials21
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02357147 | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) | Lead sponsor | Phase 2 | Terminated | Interventional | 124 | 2015-11-03 | 2020-03-17 | AMATUXIMAB, CISPLATIN, PEMETREXED | https://conductscience.org/library/trials/NCT02357147 | ClinicalTrials.gov |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | Lead sponsor | Phase 1 | Completed | Interventional | 27 | 2013-06-19 | 2024-03-29 | https://conductscience.org/library/trials/NCT01761240 | ClinicalTrials.gov | |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | Lead sponsor | Phase 1 | Completed | Interventional | 27 | 2013-11 | ONTUXIZUMAB | https://conductscience.org/library/trials/NCT01748721 | ClinicalTrials.gov | |
| NCT01574716 | Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation | Lead sponsor | Phase 2 | Completed | Interventional | 209 | 2012-08-07 | 2019-08-21 | DOCETAXEL, GEMCITABINE, ONTUXIZUMAB | https://conductscience.org/library/trials/NCT01574716 | ClinicalTrials.gov |
| NCT01521325 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | Lead sponsor | Phase 1 | Completed | Interventional | 6 | 2011-09 | AMATUXIMAB | https://conductscience.org/library/trials/NCT01521325 | ClinicalTrials.gov | |
| NCT01507545 | Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) | Lead sponsor | Phase 2 | Terminated | Interventional | 154 | 2012-03-27 | 2022-05-06 | ONTUXIZUMAB | https://conductscience.org/library/trials/NCT01507545 | ClinicalTrials.gov |
| NCT01357759 | Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects | Lead sponsor | Phase 1 | Completed | Interventional | 20 | 2013-05 | GIMSILUMAB | https://conductscience.org/library/trials/NCT01357759 | ClinicalTrials.gov | |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | Lead sponsor | Phase 2 | Completed | Interventional | 130 | 2011-06-27 | 2020-08-20 | FARLETUZUMAB | https://conductscience.org/library/trials/NCT01218516 | ClinicalTrials.gov |
| NCT01212276 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | Lead sponsor | Phase 1 | Terminated | Interventional | 18 | 2010-12 | MORAB-028 | https://conductscience.org/library/trials/NCT01212276 | ClinicalTrials.gov | |
| NCT01203618 | Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas | Lead sponsor | Phase 2 | Withdrawn | Interventional | 0 | 2011-02 | FARLETUZUMAB | https://conductscience.org/library/trials/NCT01203618 | ClinicalTrials.gov |
1 to 10 of 21
See all 21 trialsConditions69
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Ovarian Cancer | 5 |
| Pancreatic Cancer | 4 |
| Epithelial Ovarian Cancer | 3 |
| Colorectal Cancer | 2 |
| Melanoma | 2 |
| Mesothelioma | 2 |
| Non-Small Cell Lung Cancer | 2 |
| Adenocarcinoma | 1 |
| Adenocarcinoma of the Lung | 1 |
| Adult Nasal Type Extranodal NK/T-cell Lymphoma | 1 |
1 to 10 of 69Source ClinicalTrials.gov
See all 69 conditionsPartners4
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| Children's Oncology Group | Network | 1 | ClinicalTrials.gov | |
| Eisai Europe Ltd. (United Kingdom) | Industry | 1 | https://conductscience.org/library/companies/eisai-europe-ltd-united-kingdom-b261eb25 | ClinicalTrials.gov |
| National Cancer Institute (NCI) | NIH | 1 | ClinicalTrials.gov | |
| SCRI Development Innovations, LLC | Other | 1 | ClinicalTrials.gov |
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/morphotek-cf9bdcc4
GET https://conductscience.org/api/companies/v1/morphotek-cf9bdcc4/trials?page=2